Document Type
Article
Publication Date
10-12-2023
ISSN
0028-4793
Publisher
Massachusetts Medical Society
Language
en-US
Abstract
In July 2023, the Food and Drug Administration (FDA) approved Opill (norgestrel), the first over-the-counter (OTC) daily oral contraceptive pill in the United States, a move that could dramatically improve practical access to family planning. Opill’s price, however, hasn’t been made public and may not be revealed until the drug enters the market in early 2024. Although contraceptive pills generally cost between $10 and $50 per month without insurance, there’s no indication that Opill’s price will fall within this range. In addition, although the manufacturer (Perrigo) has expressed interest in a consumer-assistance program, it hasn’t released details regarding eligibility for such a program.
Recommended Citation
Christopher Robertson & Anna Braman,
The New Over-the-Counter Oral Contraceptive Pill—Assessing Financial Barriers to Access
,
in
389
The New England Journal of Medicine
1352
(2023).
Available at:
https://scholarship.law.bu.edu/faculty_scholarship/3809
Comments
From The New England Journal of Medicine, Christopher Robertson and Anna Braman, The New Over-the-Counter Oral Contraceptive Pill—Assessing Financial Barriers to Access, Volume 389, Page 1352, Copyright © 2023 Massachusetts Medical Society. Reprinted with permission.